AR080321A1 - A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE - Google Patents
A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASEInfo
- Publication number
- AR080321A1 AR080321A1 ARP110100595A AR080321A1 AR 080321 A1 AR080321 A1 AR 080321A1 AR P110100595 A ARP110100595 A AR P110100595A AR 080321 A1 AR080321 A1 AR 080321A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- entacapona
- parkinson
- disease
- composition
- Prior art date
Links
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 2
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 229960003337 entacapone Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica que comprende de 200 a 1000 mg de entacapona o sus sales, opcionalmente con otros excipientes farmacéuticamente aceptables. Reivindicacion 12: Una composicion farmacéutica que comprende alrededor de 30 mg a 300 mg de levodopa, 10 mg a 100 mg de carbidopa y 200 mg a cerca de 1000 mg de entacapona o sus sales, opcionalmente con otros excipientes farmacéuticamente aceptables.Claim 1: A pharmaceutical composition comprising 200 to 1000 mg of entacapone or its salts, optionally with other pharmaceutically acceptable excipients. Claim 12: A pharmaceutical composition comprising about 30 mg to 300 mg of levodopa, 10 mg to 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or its salts, optionally with other pharmaceutically acceptable excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110100595 AR080321A1 (en) | 2011-02-25 | 2011-02-25 | A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110100595 AR080321A1 (en) | 2011-02-25 | 2011-02-25 | A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080321A1 true AR080321A1 (en) | 2012-03-28 |
Family
ID=46003371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100595 AR080321A1 (en) | 2011-02-25 | 2011-02-25 | A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR080321A1 (en) |
-
2011
- 2011-02-25 AR ARP110100595 patent/AR080321A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122628T1 (en) | USE OF ECHO-PENTAENOIC ACID ETHYL ESTER FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA | |
| PH12018501072A1 (en) | Modified release orally administered amino acid formulations | |
| ECSP13012668A (en) | 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE | |
| ECSP11011235A (en) | DICIANOPIRIDINS ALQUILAMINO-REPLACED AND ITS AMINO ACID ESTER PROPHARMS | |
| EA201001577A1 (en) | DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION | |
| EA033067B1 (en) | Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound | |
| CL2013000063A1 (en) | A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process. | |
| MX2012010161A (en) | METHOD FOR TREATING PARKINSON EVIL. | |
| UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
| CR20150266A (en) | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | |
| PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
| CL2011001829A1 (en) | 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound. | |
| NZ591328A (en) | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof | |
| MX2019000849A (en) | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE. | |
| ECSP16005208A (en) | STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS | |
| WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof | |
| DOP2012000280A (en) | COMBINATION OF AN NSAID AND AN AMINO ACID | |
| AR080321A1 (en) | A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE | |
| AR080322A1 (en) | AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD | |
| IN2014MU01184A (en) | ||
| IN2014MU01185A (en) | ||
| AR103448A1 (en) | INTESTINAL GEL OF LEVODOPA AND CARBIDOPA AND METHODS OF USE | |
| UA102426C2 (en) | Pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity and action against nsaid induced gastropathy | |
| CL2013003070A1 (en) | 3-carboxy-n-ethyl-n, n-dimethylpropan-1-ammonium salts (2e) -3-carboxy acrylate, phosphatodihydrogen and 2,6-diohydyl-1,2,3,6-tetrahydropyrimidine-4-carboxylate; preparation procedure; and use in the treatment of cardiovascular diseases. | |
| CY1114276T1 (en) | USE OF PHYSOEXPENTOENOEIC ACID FOR HYPERTENGLERIC TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |